Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) today announced positive results from the first phase of its HIV integrase inhibitor discovery program. These results provide novel intellectual property to the Company and further validation of the CHEMSAS® drug discovery technology. The significance of these results is that the majority of currently marketed and developmental stage HIV Integrase inhibitors have a very similar way of interacting with and inhibiting the enzyme through a diketo acid type moiety...
More...
More...